keep eye on the ball

It can be testing times when the DOW shudders like it did last night. Unfortunately KSX can't control that but it has been a great achievement to receive FDA approval and this is the door opener. Based on past announcements here are some things we can expect in the short-term:

* Announcement of shipping of first batch of units as per the following statement:

'The Company is now moving into another level of operations with its ability to supply the first units, following the substantial interest shown by participants at the European Respiratory Society Meeting held in Stockholm last month. Based on a positive determination by the FDA, shipping of units to customers and Key Opinion Leaders is expected to commence shortly thereafter.'

* Results from Alfred Hospital clinical trials as per following statement:

'through its Melbourne based subsidiary, PulmoSonix Limited (“Pulmo”), received approval from the ethics committee of Melbourne’s Alfred Hospital to conduct a clinical trial in Q4 of the Acoustic Severe Asthma Monitor (ASAM)'

* Commercial arrangement announcements as per the following:

'commercial negotiations are at an advanced stage in respect of the further development, deployment and distribution of the KarmelSonix product range, including the WIM-PC and other products currently under development. A further announcement in respect of these negotiations is expected in the near term.'


There is plenty to whet the appetite for KSX in the near-term and as long as the markets hold up, the next month or two should be quite prosperous for holders.